Final rule 2026-22590
Medical Devices; Neurological Devices; Classification of the Prognostic Assessment Software of Mild Cognitive Impairment
The Food and Drug Administration (FDA) is classifying the prognostic assessment software of mild cognitive impairment into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the prognostic assessment software of mild cognitive impairment. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Source-supplied record
Document details
- Document number
- 2026-22590
- Published
- Nov 5, 2026
- Effective
- Nov 5, 2026
- Comments close
- Not supplied
- Federal Register citation
- 91 FR 69690
Docket identifiers
- Docket No. FDA-2026-N-12212
CFR references
- Title 21, part 882